Streetbeat News

Stock Prices

ARWR

MRK

NTLA

VRNA

XBI

XFOR

This week, several biotech stocks have key catalysts that could significantly impact their stock prices. Arrowhead Pharmaceuticals, Intellia Therapeutics, Merck, Verona Pharma, and X4 Pharmaceuticals are all set to release important data or have critical events. The SPDR S&P Biotech ETF also saw a rise, reflecting the sector's activity.

Portfolio Pulse from Shanthi Rexaline

June 24, 2024 | 8:51 am

TSLA

Elon Musk commented that Justin Timberlake could have avoided DWI charges if he had been driving a Tesla instead of a BMW, due to Tesla's driver assistance features. Timberlake was arrested for intoxicated driving in New York. Tesla's Full Self-Driving technology, while advanced, still requires active driver supervision.

Portfolio Pulse from Anan Ashraf

June 24, 2024 | 8:01 am

EPAC

FDS

KMX

NVDA

XAIR

Investor optimism improved despite mixed stock performance on Friday. The S&P 500 closed lower, driven by a 3% drop in Nvidia, while the Dow Jones ended marginally higher. FactSet Research Systems saw a 4% gain after strong earnings, and CarMax edged higher post-results. Investors await earnings from Enerpac Tool Group and Beyond Air.

Portfolio Pulse from Avi Kapoor

June 24, 2024 | 7:42 am

EPAC

ITI

OMIC

STOK

XAIR

Enerpac Tool Group, Singular Genomics Systems, Beyond Air, Iteris, and Stoke Therapeutics are stocks to watch on Monday. Enerpac Tool Group is expected to report earnings, Singular Genomics announced a reverse stock split, Beyond Air is expected to post a quarterly loss, Iteris filed for a mixed securities shelf offering, and Stoke Therapeutics' COO will step down.

Portfolio Pulse from Avi Kapoor

June 24, 2024 | 7:32 am

KORE

KORE Group Holdings, Inc. (NYSE:KORE) announced a 1-for-5 reverse stock split to meet NYSE listing requirements. The split will be effective on July 1, 2024, and aims to increase the per share market price. The stock will trade on a split-adjusted basis under the symbol 'KORE'.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 7:26 am

SOPH

SOPHiA GENETICS (NASDAQ:SOPH) has announced a new Residual Acute Myeloid (RAM) Application to monitor Acute Myeloid Leukemia (AML). This new tool expands their oncology portfolio and will be available globally this summer.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 7:21 am

ETHUSD

Crypto billionaire Justin Sun has reportedly purchased $49 million worth of Ethereum over the past three days, as the cryptocurrency's price dipped. This move is seen as a bullish signal ahead of the anticipated launch of spot Ethereum ETFs and follows the closure of the SEC's investigation into Ethereum's security status.

Portfolio Pulse from Aniket Verma

June 24, 2024 | 7:17 am

GUTS

Fractyl Health, Inc. (NASDAQ:GUTS) presented new preclinical data on its Rejuva pancreatic gene therapy program for obesity and type 2 diabetes at the American Diabetes Association's 84th Scientific Sessions. The study showed promising results in maintaining body composition and glycemia in a mouse model after semaglutide withdrawal.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 7:12 am

TAK

Takeda (TAK) presented positive Phase 2b trial results for mezagitamab (TAK-079) in treating primary immune thrombocytopenia (ITP). The study showed significant improvements in platelet response and reduced bleeding events. Takeda plans to initiate a global Phase 3 trial in FY2024.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 7:09 am

NRBO

NeuroBo Pharmaceuticals (NASDAQ:NRBO) announced pre-clinical data showing that its novel drug DA-1726 is superior in weight loss, lean body mass retention, and lipid-lowering effects compared to survodutide. The data will be presented at the ADA 2024 Scientific Sessions.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 7:06 am